283 related articles for article (PubMed ID: 22617751)
1. Nonalcoholic fatty liver disease and lipids.
Wierzbicki AS; Oben J
Curr Opin Lipidol; 2012 Aug; 23(4):345-52. PubMed ID: 22617751
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic fatty liver disease: current and potential therapies.
Ibrahim MA; Kelleni M; Geddawy A
Life Sci; 2013 Feb; 92(2):114-8. PubMed ID: 23159641
[TBL] [Abstract][Full Text] [Related]
3. Pathogenesis of nonalcoholic steatohepatitis (NASH).
Ma X; Li Z
Chin J Dig Dis; 2006; 7(1):7-11. PubMed ID: 16412031
[TBL] [Abstract][Full Text] [Related]
4. The treatment of NAFLD.
Trappoliere M; Tuccillo C; Federico A; Di Leva A; Niosi M; D'Alessio C; Capasso R; Coppola F; Dauria M; Loguercio C
Eur Rev Med Pharmacol Sci; 2005; 9(5):299-304. PubMed ID: 16231594
[TBL] [Abstract][Full Text] [Related]
5. Non-alcoholic fatty liver disease.
Smith BW; Adams LA
Crit Rev Clin Lab Sci; 2011; 48(3):97-113. PubMed ID: 21875310
[TBL] [Abstract][Full Text] [Related]
6. The metabolic syndrome and nonalcoholic fatty liver disease.
Collantes RS; Ong JP; Younossi ZM
Panminerva Med; 2006 Mar; 48(1):41-8. PubMed ID: 16633331
[TBL] [Abstract][Full Text] [Related]
7. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
Takahashi Y; Sugimoto K; Inui H; Fukusato T
World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
[TBL] [Abstract][Full Text] [Related]
8. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Younossi ZM
Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
[TBL] [Abstract][Full Text] [Related]
9. [Nonalcoholic steatohepatitis: pathogenesis and treatment].
Park SH
Korean J Hepatol; 2008 Mar; 14(1):12-27. PubMed ID: 18367854
[TBL] [Abstract][Full Text] [Related]
10. Thiazolidinediones and the liver in humans.
Yki-Järvinen H
Curr Opin Lipidol; 2009 Dec; 20(6):477-83. PubMed ID: 19779336
[TBL] [Abstract][Full Text] [Related]
11. Current pharmacological treatment of nonalcoholic fatty liver.
Portincasa P; Grattagliano I; Palmieri VO; Palasciano G
Curr Med Chem; 2006; 13(24):2889-900. PubMed ID: 17073635
[TBL] [Abstract][Full Text] [Related]
12. Effects of bezafibrate in nonalcoholic steatohepatitis model mice with monosodium glutamate-induced metabolic syndrome.
Sasaki Y; Shimada T; Iizuka S; Suzuki W; Makihara H; Teraoka R; Tsuneyama K; Hokao R; Aburada M
Eur J Pharmacol; 2011 Jul; 662(1-3):1-8. PubMed ID: 21549692
[TBL] [Abstract][Full Text] [Related]
13. Nutritional modulation of nonalcoholic fatty liver disease and insulin resistance: human data.
Yki-Järvinen H
Curr Opin Clin Nutr Metab Care; 2010 Nov; 13(6):709-14. PubMed ID: 20842026
[TBL] [Abstract][Full Text] [Related]
14. Role of fatty acids in the pathogenesis of obesity and fatty liver: impact of bariatric surgery.
Verna EC; Berk PD
Semin Liver Dis; 2008 Nov; 28(4):407-26. PubMed ID: 18956297
[TBL] [Abstract][Full Text] [Related]
15. Fatty liver: role of inflammation and fatty acid nutrition.
Byrne CD
Prostaglandins Leukot Essent Fatty Acids; 2010; 82(4-6):265-71. PubMed ID: 20189787
[TBL] [Abstract][Full Text] [Related]
16. Emerging drugs for non-alcoholic steatohepatitis.
Tomeno W; Yoneda M; Imajo K; Ogawa Y; Kessoku T; Saito S; Eguchi Y; Nakajima A
Expert Opin Emerg Drugs; 2013 Sep; 18(3):279-90. PubMed ID: 23848366
[TBL] [Abstract][Full Text] [Related]
17. Pharmacologic management of nonalcoholic fatty liver disease.
Harrison SA; Neuschwander-Tetri BA
Clin Liver Dis; 2004 Aug; 8(3):715-28, xii. PubMed ID: 15331071
[TBL] [Abstract][Full Text] [Related]
18. Metformin prevents liver tumorigenesis induced by high-fat diet in C57Bl/6 mice.
Tajima K; Nakamura A; Shirakawa J; Togashi Y; Orime K; Sato K; Inoue H; Kaji M; Sakamoto E; Ito Y; Aoki K; Nagashima Y; Atsumi T; Terauchi Y
Am J Physiol Endocrinol Metab; 2013 Oct; 305(8):E987-98. PubMed ID: 23964070
[TBL] [Abstract][Full Text] [Related]
19. Lipid-lowering agents in nonalcoholic fatty liver disease and steatohepatitis: human studies.
Nseir W; Mograbi J; Ghali M
Dig Dis Sci; 2012 Jul; 57(7):1773-81. PubMed ID: 22419057
[TBL] [Abstract][Full Text] [Related]
20. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Stein LL; Dong MH; Loomba R
Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
